Related Experiment Videos
Antitumor effect of novel silatranes on renal cell carcinoma in mice
1Department of Microbiology and Immunology, Northeastern Ohio Universities College of Medicine, Rootstown 44272.
Abstract:
The effect of several novel silatrane derivatives on the growth of syngeneic renal cell carcinoma (RENCA) in BALB/c mice and the survival rate of the animals were evaluated. The RENCA-bearing animals were treated subcutaneously and weekly with either a water-insoluble or a water-soluble derivative. The silatrane-treated animals were either free of palpable tumors or developed tumors much more slowly in comparison with the control animals without silatranes. The treated animals as a whole also died of tumor at much slower rates. Attempts to use higher silatrane dosages to achieve better curative effects were hampered by the toxicity of these compounds.
Insights
Novel silatrane derivatives showed significant potential in inhibiting renal cell carcinoma (RENCA) growth and improving survival rates in mice. However, compound toxicity limited higher dosage efficacy.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Renal cell carcinoma (RENCA) is a significant health concern.
- Novel therapeutic agents are needed to combat RENCA progression.
- Silatrane derivatives represent a class of compounds with potential pharmacological activity.
Purpose of the Study:
- To evaluate the efficacy of novel silatrane derivatives against syngeneic renal cell carcinoma (RENCA) in BALB/c mice.
- To assess the impact of silatrane treatment on tumor growth and animal survival rates.
Main Methods:
- BALB/c mice bearing RENCA were treated weekly with water-insoluble or water-soluble silatrane derivatives.
- Tumor growth and animal survival were monitored and compared to control groups.
Main Results:
- Silatrane treatment resulted in the absence of palpable tumors or significantly slower tumor development compared to controls.
- Animals treated with silatranes exhibited markedly reduced mortality rates due to tumors.
- Higher dosages of silatranes, while aiming for enhanced effects, were limited by observed toxicity.
Conclusions:
- Novel silatrane derivatives demonstrate promising anti-tumor activity against RENCA in a murine model.
- Silatranes can inhibit tumor growth and prolong survival, suggesting therapeutic potential.
- Further research is needed to optimize silatrane compounds, balancing efficacy with reduced toxicity for clinical application.